Exploring Protein-Based Therapies to Treat Muscular Dystrophies (Podcast)

MDA research grantee Michael Rudnicki talked with MDA on Dec. 17, 2012, about how the WNT7a protein increased the numbers of muscle repair cells and the size and strength of muscle fibers in a mouse model of Duchenne muscular dystrophy. Rudnicki also discussed the advantages and disadvantages of developing protein-based therapies versus cell-based therapies to treat muscle disease. A clinical trial of a WNT7a-based therapy in Duchenne MD is being planned. This podcast complements the Nov. 27, 2012, Quest news story WNT7a Injections Restore Strength in DMD Mice.

No votes yet